Retrophin (NASDAQ:RTRX) Stock Price Up 6%

Share on StockTwits

Retrophin Inc (NASDAQ:RTRX) rose 6% during mid-day trading on Friday . The stock traded as high as $12.86 and last traded at $12.85, approximately 368,447 shares changed hands during trading. A decline of 23% from the average daily volume of 481,191 shares. The stock had previously closed at $12.12.

Several equities analysts have commented on RTRX shares. William Blair reiterated a “buy” rating on shares of Retrophin in a research report on Friday, August 23rd. Jefferies Financial Group set a $33.00 target price on shares of Retrophin and gave the stock a “buy” rating in a research note on Friday, August 23rd. ValuEngine upgraded shares of Retrophin from a “hold” rating to a “buy” rating in a research note on Wednesday, October 2nd. BidaskClub upgraded shares of Retrophin from a “strong sell” rating to a “sell” rating in a research note on Thursday, October 31st. Finally, Zacks Investment Research upgraded shares of Retrophin from a “hold” rating to a “strong-buy” rating and set a $14.00 price target on the stock in a research note on Wednesday. One analyst has rated the stock with a sell rating, ten have issued a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $27.75.

The company has a market capitalization of $532.63 million, a PE ratio of -5.06 and a beta of 0.79. The company’s 50 day simple moving average is $11.72 and its 200 day simple moving average is $16.50. The company has a debt-to-equity ratio of 0.82, a current ratio of 5.00 and a quick ratio of 4.94.

Retrophin (NASDAQ:RTRX) last issued its quarterly earnings results on Wednesday, October 30th. The biopharmaceutical company reported ($0.55) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.10) by $0.55. Retrophin had a negative return on equity of 43.88% and a negative net margin of 71.70%. The firm had revenue of $44.37 million for the quarter, compared to analyst estimates of $45.31 million. During the same period last year, the company earned ($0.68) EPS. The firm’s quarterly revenue was up 9.0% on a year-over-year basis. On average, equities analysts forecast that Retrophin Inc will post -3.45 EPS for the current year.

Hedge funds have recently bought and sold shares of the business. Perceptive Advisors LLC raised its holdings in shares of Retrophin by 23.5% in the 2nd quarter. Perceptive Advisors LLC now owns 3,772,582 shares of the biopharmaceutical company’s stock worth $75,791,000 after buying an additional 717,875 shares in the last quarter. Vanguard Group Inc. increased its stake in Retrophin by 3.5% in the 2nd quarter. Vanguard Group Inc. now owns 2,192,002 shares of the biopharmaceutical company’s stock valued at $44,036,000 after buying an additional 73,736 shares during the last quarter. Rock Springs Capital Management LP increased its stake in Retrophin by 14.5% in the 2nd quarter. Rock Springs Capital Management LP now owns 950,000 shares of the biopharmaceutical company’s stock valued at $19,086,000 after buying an additional 120,000 shares during the last quarter. D. E. Shaw & Co. Inc. increased its stake in Retrophin by 3.9% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 891,667 shares of the biopharmaceutical company’s stock valued at $17,914,000 after buying an additional 33,078 shares during the last quarter. Finally, Nuveen Asset Management LLC purchased a new stake in Retrophin in the 2nd quarter valued at about $14,273,000.

Retrophin Company Profile (NASDAQ:RTRX)

Retrophin, Inc, a biopharmaceutical company, focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.

See Also: Yield Curve

Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.